Skip to main content

Drug Interactions between Granix and levamisole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

levamisole tbo-filgrastim

Applies to: levamisole and Granix (tbo-filgrastim)

ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.

MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.

References

  1. (2002) "Product Information. Neupogen (filgrastim)." Amgen
  2. (2001) "Product Information. Leukine (sargramostim)." Immunex Corporation
  3. (2001) "Product Information. Stemgen (ancestim)." Amgen
  4. (2013) "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

levamisole food

Applies to: levamisole

GENERALLY AVOID: Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol. These side effects could be alleviated by total abstinence from alcohol. No mechanism has been established for this interaction.

MANAGEMENT: Patients receiving levamisole should avoid alcohol.

References

  1. (2001) "Product Information. Ergamisol (levamisole)." Janssen Pharmaceuticals
  2. Renoux G (1980) "The general immunopharmacology of levamisole." Drugs, 19, p. 89-99
  3. Renoux G (1978) "Modulation of immunity by levamisole." Pharmacol Ther [B], 2, p. 397-422

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer